Grifols GIFLF
NASDAQ GIFLF
$11.08 +0.00 (+0.00%)
At close: Sep 8, 2026 · 4:00 PM EDT

Grifols (GIFLF) Other Accumulated Expenses (2009 - 2025)

Grifols' (GIFLF) quarterly Other Accumulated Expenses came in at $642.6 million in Q4 2025, down 11.05% on a YoY basis from $722.4 million in Q4 2024, and down 11.05% quarter-over-quarter from $722.4 million in Q4 2024.

Analysis

Grifols (GIFLF) Other Accumulated Expenses (2009 - 2025) Analysis & Trends

Grifols (GIFLF) has reported Other Accumulated Expenses for 17 consecutive years, with $642.6 million the latest figure, recorded in Q4 2025.

  • For the quarter ending Q4 2025, Other Accumulated Expenses fell 11.05% year-over-year to $642.6 million; the trailing twelve-month figure through Dec 2025 stood at $642.6 million (down 11.05% YoY), and the FY2025 full-year result was $623.7 million, down 13.67% from the prior year.
  • Other Accumulated Expenses declined to $642.6 million in Q4 2025 per GIFLF's latest filing, from $722.4 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $1.1 billion in Q4 2023 and bottomed at $250.8 million in Q4 2021.
  • Historically, Other Accumulated Expenses has averaged $706.9 million across 5 years, with a median of $722.4 million in 2024.
  • The sharpest annual moves came in 2022 and 2024: Other Accumulated Expenses soared 225.77% in 2022, then sank 34.41% in 2024.
  • Over 5 years, Other Accumulated Expenses stood at $250.8 million in 2021, then jumped by 225.77% to $817.2 million in 2022, then jumped by 34.78% to $1.1 billion in 2023, then tumbled by 34.41% to $722.4 million in 2024, then fell by 11.05% to $642.6 million in 2025.
  • According to Business Quant data, Other Accumulated Expenses over the past three periods registered $642.6 million, $722.4 million, and $1.1 billion for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 203.97 Bn 189.99 Bn 7.24 Bn
2 Gilead Sciences 178.74 Bn 175.56 Bn 6.22 Bn
3 Vertex Pharmaceuticals 130.73 Bn 122.88 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 80.42 Bn 72.42 Bn 3.93 Bn
5 Argenx Se 60.40 Bn 55.21 Bn 1.37 Bn
6 Moderna 57.65 Bn 52.52 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 33.37 Bn 30.07 Bn 992.69 Mn
8 Biogen 32.15 Bn 30.86 Bn 1.96 Bn
9 Roivant Sciences 29.58 Bn 29.58 Bn 1.16 Mn
10 Grifols 7.54 Bn 9.09 Bn 3.33 Bn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 642.55 Mn
Dec 31, 2024 722.37 Mn
Dec 31, 2023 1.10 Bn
Dec 31, 2022 817.16 Mn
Dec 31, 2021 250.84 Mn
Dec 31, 2020 182.61 Mn
Sep 30, 2020 1.08 Bn
Mar 31, 2020 1.11 Bn
Dec 31, 2019 218.50 Mn
Sep 30, 2019 1.09 Bn
Dec 31, 2018 193.11 Mn
Sep 30, 2018 975.69 Mn
Jun 30, 2018 165.40 Mn
Mar 31, 2018 1.09 Bn
Dec 31, 2017 170.02 Mn
Jun 30, 2017 141.55 Mn
Dec 31, 2016 151.36 Mn
Sep 30, 2016 133.26 Mn
Jun 30, 2016 125.37 Mn
Dec 31, 2015 147.61 Mn